corinnova CEO and leadership

John Criscione is the Director of the Cardiac Mechanics Lab and Professor of Biomedical Engineering at Texas A&M University (TAMU). Dr. Criscione provides general consulting to the company, assisting in prototyping and pre-clinical animal studies as needed, and continues to make significant contributions to new inventions and key new patents relating to the core technology. Dr. Criscione earned his MD and PhD in Biomedical Engineering from Johns Hopkins University.

Ms. Motter has over thirty years of experience in both public and privately held companies. She earned her M.B.A. from the UCLA Anderson School of Management and worked as an Auditor with KPMG prior to entering the private sector working in life science, manufacturing, service, and import/export industries. Ms. Motter has been involved with companies in all stages of development, including founding, pre-IPO, IPO, follow-on and M&A activities. She has been the CFO for many life science companies including: Ensysce BioSciences, Inc., N3D BioSciences, Inc., CorInnova Inc., LifeCell, Repros Chrysalis, BioTherapeutics, Inc., ProlX, and Aronex.

John Criscione is the Director of the Cardiac Mechanics Lab and Professor of Biomedical Engineering at Texas A&M University (TAMU). Dr. Criscione provides general consulting to the company, assisting in prototyping and pre-clinical animal studies as needed, and continues to make significant contributions to new inventions and key new patents relating to the core technology. Dr. Criscione earned his MD and PhD in Biomedical Engineering from Johns Hopkins University.

Ms. Motter has over thirty years of experience in both public and privately held companies. She earned her M.B.A. from the UCLA Anderson School of Management and worked as an Auditor with KPMG prior to entering the private sector working in life science, manufacturing, service, and import/export industries. Ms. Motter has been involved with companies in all stages of development, including founding, pre-IPO, IPO, follow-on and M&A activities. She has been the CFO for many life science companies including: Ensysce BioSciences, Inc., N3D BioSciences, Inc., CorInnova Inc., LifeCell, Repros Chrysalis, BioTherapeutics, Inc., ProlX, and Aronex.